

Charity registration number: 266813
Company registration number: 349408

SOCIETY FOR ENDOCRINOLOGY
(A COMPANY LIMITED BY GUARANTEE)

FINANCIAL STATEMENTS
For the year ended 31 July 2014



SOCIETY FOR ENDOCRINOLOGY

FINANCIAL STATEMENTS – For the year ended 31 July 2014

INDEX

Section	Page
1 Overview	
Report of the Council of Management	1 - 12
Independent Auditor's Report	13
2 Consolidated financial statements	
Consolidated statement of financial activities incorporating the income and expenditure account	14
Consolidated and Charity balance sheets	15
Consolidated Cashflow statement	16
Notes to the accounts	17 - 26
3 Detailed report to the members – unrestricted funds	
Main Fund:	
• income and expenditure account	27 - 28
• balance sheet	29
Designated funds:	
• Designated Strategy Fund	30
• Designated Refurbishment Fund	31
4 Restricted Funds	
The Marjorie Robinson Fund	32
Acromegaly Fund	33
CaHASE Fund	34
Pituitary Apoplexy	35
Graves' Disease	36
Transition Study	37

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Reference and administrative details of the charity, its Trustees and advisors

The Society for Endocrinology is a company limited by guarantee governed in accordance with its Memorandum and Articles of Association.

The administrative information required to be given is as follows:

Charity Registration No: 266813

Company Registration No: 349408

Principal and registered Office: 22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT

Council of Management: Professor S P O'Rahilly (President)
Professor D W Ray (General Secretary)
Professor G R Williams (Treasurer)
Professor C J McCabe (Programme Secretary)
Professor E Davies
Professor W Dhillon
Dr M Gibson
Professor N A Hanley
Professor A Logan
Professor J R Seckl
Professor A P Weetman
Professor A White

Senior Staff: Mr L Heward-Mills (Chief Executive & Company Secretary)
Mrs P A Barter (Finance & Administration Director)
Ms R A Evans (Head of Membership & Professional Affairs)
Ms H Gregson (Client Services Director)
Ms T Horner (HR & Performance Manager)
Ms K Spiller (Head of Publishing)
Mr R Cropley (Head of IT & Business Systems)

No staff are registered as directors of the Society at Companies House. The term 'director' is used for internal purposes only.

Auditor: haysmacintyre
Chartered Accountants
26 Red Lion Square
London
WC1R 4AG

Solicitors: Royds
65 Carter Lane
London
EC4V 5HF

Bankers: National Westminster Bank plc
Thornbury Branch
P O Box 1369
Bristol BS99 5HD
HSBC Bank plc
27 Gloucester Road North
Filton
Bristol BS27 0SQ

Investment Managers: Brewin Dolphin Limited
2nd Floor
5 Callaghan Square
Cardiff

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Introduction

The Society for Endocrinology (“the Society”) is a charity and a company limited by guarantee. Its members are scientists, doctors, nurses and students with an involvement in endocrinology. The Society’s beneficiaries are its members, endocrine patients and their representative groups, students and schoolchildren, and the general public. The Society provides a range of public benefits aimed at providing educational and research support to these groups and these benefits are detailed in the body of this report.

Many endocrine disorders are very common and it is likely that over half of the population will suffer from an endocrine disorder at some point in their lives. For example, one in three women and one in ten men over 65 will suffer an osteoporotic fracture. One in six women have polycystic ovary syndrome and a similar proportion of women over 65 have mild hypothyroidism. In addition, there are a large number of rarer endocrine conditions, including for example Cushing’s disease, acromegaly, multiple endocrine neoplasia and congenital adrenal hyperplasia.

The Society’s current strategy was agreed by the Trustees in January 2012. The longer term goal is to establish the Society for Endocrinology as a world leading authority on hormones. This will be realised through the completion of a series of projects approved by Council of Management (Council) and scheduled to run between 2012 and 2016. Each project falls within one of five strategic initiative themes: (a) maximise appeal and value to members and non members, (b) be a central gateway to hormone information and knowledge resources, (c) advocate and lobby in support of endocrinology, (d) develop international presence and (e) collaborate with targeted societies and organisations.

Progress against the plan is monitored through regular updates to the Trustees and to the Society’s Council.

Structure, governance and management

The Society was established in 1939 and attained charitable status in 1961. Its governing documents are the Memorandum and Articles of Association, supported by the Bylaws.

The Society is governed by the Council consisting of twelve elected members, fulfilling the dual roles of trustees and directors of the Society. In addition, Committee chairs sit on Council in an ex officio capacity and the Chairman of Bioscientifica Limited and a Young Endocrinologist representative attend Council meetings as observers. Neither the ex officio members nor the observers have a vote and are not trustees or directors.

Officers-elect are invited to attend Council and relevant committee meetings during their shadow year, but are not entitled to vote and are not trustees or directors.

Any Full Member of the Society may nominate any other Full Member for vacant Council positions. If there are more nominations than vacancies, the Full Members are balloted and the result announced at the AGM.

Four of the Council members are designated Officers of the Society. These are the President, General Secretary, Treasurer and Programme Secretary. They are elected specifically to these posts one year in advance of taking office and serve a total of three years in their elected post, except the Treasurer, whose term of office is five years. Other Council members serve a four-year term.

On appointment, and usually before their first Council meeting, all new Council members are invited to attend an induction session. This covers governance, finance and the major areas of activity and is a mixture of information and discussion. Each new Council member is then presented with a Council Reference File that contains all the necessary reference information. Ad hoc trustee briefings are provided on appropriate changes in legislation and requirements.

The Society currently has eight committees, which report to Council through their Chair. These are:

Clinical Committee	Public Engagement Committee
Finance Committee	Programme Committee
Nominations Committee	Publications Committee
Nurse Committee	Science Committee

In addition, there is an Officers Sub-committee of Council that handles day-to-day management issues and preparation for Council meetings, a Remuneration Group that manages salaries, bonuses and other staff benefits,

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Structure, governance and management (Continued)

a Corporate Liaison Board which provides a forum for two-way communication and advice between the Society and industry and a Young Endocrinologists' Steering Group which is responsible for the Society's strategy and activity for trainee members.

Committee chairs are appointed by Council, with the exception of the Programme Committee (chaired by the Programme Secretary) and the Finance Committee (chaired by the Treasurer). The Chairman of the Publications Committee is a Trustee of the Society and normally the General Secretary. Committees have a degree of autonomy as regards their composition and methods of election/appointment, but always subject to Council's approval. Council reviews the structure and remits of committees from time to time.

Members of the Council serve on the committees, sub-committees and groups of the Society as follows:

Professor K Chapman	Publications, Science
Dr H Christian	Publications
Professor E Davies	Programme
Professor W S Dhillon	Public Engagement
Professor A B Grossman	Officers, Nominations, Publications, Remuneration (to March 2014)
Professor Ann Logan	Finance (to December 2013)
Professor C J McCabe	Officers, Programme, Science
Professor S O'Rahilly	Officers, Nominations, Publications, Remuneration (from March 2014)
Professor D W Ray	Officers, Clinical, Nominations, Publications, Remuneration
Professor R Sharpe	Public Engagement (to March 2014)
Professor Anne White	Nominations
Professor G R Williams	Officers, Finance, Publications, Remuneration

Council also appoints the Editors-in-Chief of the three journals owned by the Society, of the Society's magazine, *The Endocrinologist* and in conjunction with the Executive Committee of the European Society of Endocrinology (ESE), the Editor-in-Chief of *Endocrine Connections*, a journal co-owned by the Society and ESE.

There are role descriptions in place for all Council roles, staff, committees and editors. The Society's staff report to the General Secretary through the Chief Executive.

In 1996, the Society set up a trading subsidiary, Bioscientifica Limited, to raise funds for the Society by providing services to third parties. Bioscientifica Limited's board of directors includes two Officers of the Society, together with several other directors who are not Council members. The Chief Executive of the Society is the Managing Director of Bioscientifica Limited, and the Finance & Administration Director and Client Services Director are also directors. The number of non-executive directors always exceeds the number of executive directors. Bioscientifica remits profits to the Society by Gift Aid, after making provision for the retention of profit for future use and other commitments.

Wider networks and collaborations

The Society recognises that some of its aims can best be achieved by collaboration with other organisations. To this end, the Society is a member of the Society of Biology, a single unified voice for biology, whose activities include advising Government and influencing policy and advancing education and professional development.

The Society is a member of the Parliamentary & Scientific Committee, the Foundation for Science and Technology, Understanding Animal Research, the Association of Medical Research Charities, the Association of Learned and Professional Society Publishers, the International Association of Scientific, Technical and Medical Publishers and Sense About Science's Voice of Young Science network.

The Society is an active member of the international endocrine community. As such, it is a member of the International Society of Endocrinology and the European Society of Endocrinology. With the latter, it has set up an alliance whereby three of the Society's journals are also official journals of the European Society, and one is co-owned with the European Society.

The Society also collaborated with the European Society for Endocrinology, The Endocrine Society (the US Society) and the Indian Society of Endocrinology to hold the International Clinical Update in Endocrinology in Hyderabad, India in February 2014. Excellent feedback was received for this event.

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Structure, governance and management (Continued)

The Society also has an agreement with Wiley-Blackwell, whereby their journal *Clinical Endocrinology* is an official journal of the Society.

Strategic report

General overview

Objectives and activities

The object of the Society for Endocrinology is the advancement of public education in endocrinology. This involves projects to inform and educate the public directly, projects to educate and promote research in science, and projects to educate and promote best practice in clinical endocrinology for the public benefit. In furtherance of its objective, the Society has powers to carry out a range of activities, including owning and publishing journals devoted to advancing knowledge of endocrinology.

The Society's long-term charitable objectives are:

1. To advance scientific and clinical education and research in endocrinology for the public benefit
2. To educate and inform the public on all aspects of endocrinology
3. To attract good young scientists, doctors and nurses into endocrinology and to retain them in the discipline, in order to improve science and medicine for the public benefit
4. To raise the profile and be the voice of endocrinology in the UK
5. To promote and support endocrinology worldwide and to foster a sense of community, including working in collaboration with other international organisations.

The Society's main policies to date have been to promote endocrinology for the public benefit by:

1. Publishing journals and a magazine in the field of endocrinology, to provide education and research resources for scientists, clinicians, nurses and the public
2. Organising conferences and training courses in endocrinology, thus providing educational resources for scientists, doctors, nurses and the public
3. Providing a range of grants to attract high-calibre scientists, doctors and nurses into endocrinology and enable them to contribute effectively to forwarding the science and medicine of endocrinology
4. Awarding medals to recognise outstanding contributions to endocrinology; the recipients lecture at the Society's annual meeting and the abstracts are available free to the public
5. Carrying out public relations activities, including management of a substantial public website, to improve public understanding of the hormone system and the diseases and issues associated with it
6. Supporting patient advocacy groups in endocrinology by means of advice and grants, with a view to improving information and care for patients and carers
7. Ensuring that external bodies, including government departments, higher education bodies, and scientific and medical NGOs, are fully aware of the views of the endocrine community on matters scientific and medical, thus promoting best practice in science and medicine
8. By means of a wholly-owned trading subsidiary, Bioscientifica Limited, to raise funds for the Society by providing products and services to third parties in areas where the Society's staff have expertise
9. Co-ordinating collaborative research projects aimed at disseminating improved information on rare endocrine diseases.

The Council have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

Achievements and performance

The Society has maintained the breadth and depth of its existing activities, whilst putting plans in place to complete specific reviews of public engagement, membership and education. These activities form part of the Society's plan to reduce reserves and improve its impact on the future of endocrinology.

The objectives and achievements for each area of activity during the year are highlighted:

Membership

Objectives and activities

The Society's membership comprises basic and clinical scientists, clinicians, nurses and students. There are eight categories of membership: Honorary, Senior, Full, Clinician-in-Training, Nurse, Scientist-in-Training, Associate and Student. All categories are eligible to be beneficiaries of the Society's charitable activities and Full, Associates, Nurses, Scientists-in-Training and Clinicians-in-Training are eligible to be beneficiaries of the

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Membership (Continued)

Society's grants. Those taking advantage of the free Student Membership are eligible for the SfE BES free places and Summer Studentship grants. Only Full Members are eligible to vote in elections. The Society communicates with its members via the quarterly magazine, monthly and ad hoc email alerts, Twitter, Facebook and the website.

Achievements and performance

Membership numbers are growing, with 2,291 at December 2013 (2,278 at December 2012). The continued focus on both attracting new members and regaining lapsed members has shown a degree of success and this momentum will be maintained into 2014-15.

Corporate supporters

Objectives and activities

The Society also engages a cross-section of industry through the Corporate Supporters scheme. Participants of the scheme elect representatives to the Corporate Liaison Board, which serves as a forum for two-way communication and advice between the Society and industry, regarding for example, regulatory issues, therapeutic development and endocrinology issues.

Achievements and performance

Engagement with industry representatives achieved 1 Platinum Supporter and 3 Gold Supporters and 5 Silver Supporters.

Publications

Objectives and activities

The Society owns three established, world-class research journals (*Journal of Endocrinology*, *Journal of Molecular Endocrinology* and *Endocrine-Related Cancer*) all of which are published by Bioscientifica and publishes its own magazine (*The Endocrinologist*). *Endocrine Connections*, is a jointly owned Open Access journal with the European Society of Endocrinology and continues to fulfil the Society's objective to broaden its research base and provide a solid platform in open access publishing. The Society also endorses *Endocrinology*, *Diabetes & Metabolism Case Reports* a unique, Open Access resource that publishes and links together case reports, enabling practitioners to communicate findings, share knowledge and convey medical experiences efficiently and effectively; furthering both medical education and clinical practice. Society members are entitled to a discounted open access charge.

The Society also has an agreement with Wiley whereby a fifth journal, *Clinical Endocrinology*, is designated the Society's official clinical journal. The journals have a global authorship and reach. All subscribed content is available free to members via the secure member area of the website.

The magazine is primarily aimed at educating endocrinologists and informing them of grants and other support, and fostering a sense of community; it is also distributed to some non-members and is available free to the public on the Society's website.

The Society's publications are its largest area of charitable activity financially, accounting for about two-thirds of the total income from charitable activities. In addition, publishing is an important activity for Bioscientifica extending beyond the Society's own publications.

Achievements and performance

The financial health of the publishing programme has been maintained despite a continuing adverse environment in many subscribing countries and ongoing uncertainties about the future. One of the main measures of success for journals is the impact factor, a measure of how often an article is cited by other authors. One of the objectives for the journals was to achieve impact factors above 3, and this has been successful for all of the titles, as shown by the latest impact factors (previous year in brackets):

<i>Journal of Endocrinology</i> (JOE)	3.586	(4.058)
<i>Journal of Molecular Endocrinology</i> (JME)	3.621	(3.577)
<i>Endocrine-Related Cancer</i> (ERC)	4.907	(5.261)
<i>Clinical Endocrinology</i> (CE)	3.353	(3.396)

The next objective as been identified to establish the core journals in the top quartile of their impact factors category.

The Society remains an active participant in the current debate on the future of research communication, and of the place of journals within it.

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Conferences, events and training activities

Objectives and activities

The Society organises the UK's major endocrine conference each year – the annual Society for Endocrinology BES meeting, which is held in a variety of locations around the country. This conference promotes research and education for the benefit of endocrinologists and also of the general public. It raises the profile of endocrinology by associated media work and also by placing all abstracts on the web free to all.

The Society organises Clinical Update, the annual national training course for trainee doctors specialising in endocrinology. The Society continues to work in partnership with the RCP and other specialist societies with regard to the examination programme for specialist clinical trainees. Furthermore, the Society organises three Clinical Cases training days each year, a National one in London and two Regional ones elsewhere in the UK. In addition, an annual career development programme is run for the education of early career researchers and, for specialist nurses, there is an annual educational update on best practice.

Achievements and performance

The SfE BES annual meeting held in Liverpool in March 2014 attracted 1107 attendees including delegates, speakers, staff and exhibitors (2013 – 1015 attendees) and received 477 submitted abstracts (2013 – 433). A gross deficit of £87K was incurred.

The Clinical Update, held in Bristol in November 2013, attracted 189 delegates (2012 - 173) and produced very good feedback from delegates and faculty alike. The first Regional Clinical Cases Meeting of the year was held in December 2013 in Belfast and attracted 62 total attendees (Leeds 2012 – 43). The second was held in Dundee in May 2014 and attracted 68 total attendees (Newport, 2013 – 73). The Clinical Cases Meeting in London in February 2014 attracted 90 delegates, (2013 - 68). Together, these events generated a gross deficit of £16K (2013 £30K deficit).

Conferences and training activities generate about one fifth of the income from charitable activities, as well as some commercial income.

Grants and other awards

Objectives and activities

The Society's grant programme exists to attract and support good doctors, scientists and nurses, along with providing support for public and patient support group activities. In addition to grants, the Society awards a number of medals and prizes annually, including the Dale, Society, European, Transatlantic, and Hoffenberg International Medals. The Jubilee medal is awarded on an occasional basis. The Society continues to offer an Undergraduate Essay Prize, intended to encourage scientist, medical and veterinary students to consider a career in endocrinology.

2014 saw the establishment of the SfE Journal Awards. These Awards recognise excellence in endocrine research and practice in addition to wider contribution to the biomedical and biological sciences field.

The Society is a member of the Association of Medical Research Charities (AMRC) and its grant assessment processes have been awarded the AMRC Certificate of Best Practice in Medical and Health Research Peer Review.

Achievements and performance

A total of £591K (2013 - £675K) was given out in grants and £46K (2013 - £30K) in awards. Of the grants, £5K (2013 - £4K) was funded by the Marjorie Robinson Fund, whilst there was no funding from third parties (2013 - £nil). The value of conference grants paid decreased to £173K (2013 - £186K). Early Career grants to the value of £263K were paid (2013 - £361K). Summer Studentships were awarded at a value of £65K (2013 - £68K).

The Society's Public Engagement Grant scheme continues to provide Society members with funding to carry out their own science communication projects. During the financial year, three Public Engagement Grants were awarded. The team continues to work closely with endocrine patient support groups and administer the Patient Support Grant scheme which provides funding for patient groups to carry out projects they would not otherwise be able to afford. In 2014, seven Patient Support Grants were awarded to the combined value of £26K. An additional Patient Travel Grant scheme was launched this year, through which £8K was distributed to patient groups to support travel to Society events and telephone helpline training.

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Grants and other awards (Continued)

Interest in the Undergraduate Achievement Award remains steady with 8 being awarded in the period (11 in 2013). The Society's five annual medals were awarded at SfE BES 2014, plus the 2013 Dale medal lecture which had been held over for reasons of ill health. The 2014 Undergraduate Essay Prize attracted slightly fewer entries than the previous year, 66 compared to 88. Entries were received from a variety of students, science, medical and veterinary

The number of grant applications and awards are shown in the following table:

	Year to 31 July 2014		Year to 31 July 2013	
	Applications	Awarded	Applications	Awarded
Conference grants	271	232	263	224
SfE BES free places	44	38	86	59
Early career grants programme	43	26	49	37
Summer studentships	33	23	33	26
Patient support grants	20	20	0	0
Public engagement grants	3	3	3	1
Undergraduate achievement awards	6	6	11	11
Practical Skills grants	10	6	11	9
Sponsored Seminar grants	13	10	10	10
Other	3	3	4	2
Total	446	367	470	379

The costs associated with these grants are disclosed in note 7 to the accounts.

Public and media relations

Objectives and activities

The Public Engagement Committee supports the Public and Media Relations team in their activities, which include raising the profile of endocrinology by working with the media proactively and reactively to promote public awareness of issues in endocrinology and to ensure that the media have access to accurate and impartial information. The team also organises media training for Society members.

The Society's public and media relations activities include the provision of education to the general public, dealing with public enquiries and organising debates and on events centred around topical areas of endocrinology. The Society's public information website, You & Your Hormones (www.yourhormones.info) provides reliable, scientifically accurate information on hormones and hormone-related conditions in line with the Society's public benefit objective.

Achievements and performance

The Society's science communication work continues to be overseen by the Public Engagement Committee. The Society obtained excellent media coverage for the annual SfE BES conference with a total of 280 articles in 19 countries.

During the financial year the Society organised four public events. The first two events at Brighton Science Festival in February and at Edinburgh International Science Festival in April addressed the role of different hormones in attraction. Two further events were held at Cheltenham Science Festival in June, on hormones in attraction, and the late endocrine effects of cancer therapy. These events attracted a combined audience of almost 450 people.

The Society's public information website, *You & Your Hormones* (www.yourhormones.info) continues to run successfully. The website currently has over 130 articles on hormones and hormone-related conditions. Website visits increased by 72% on the previous year.

Other educational and professional activities

Objectives and activities

The Society's programme of activities includes:

- Working closely with the Society of Biology on a range of topics aimed at promoting the biosciences for the public benefit and at educating and supporting scientists.

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Investment policy and performance (Continued)

- Maintaining a large website with research, clinical and education information for use by endocrinologists and the public.
- Establishing Endocrine Networks to replace and enhance the work of the previous Special Interest Groups.
- Managing a number of clinical research projects with the aim of improving knowledge of these diseases, educating clinicians about this and thereby improving patient care.
- Developing, updating and publishing clinical guidelines with the aim of supporting best practice in the specialty.
- Running a Certificate in Adult Endocrine Nursing, with the aim of furthering nurse education.
- Managing a programme of clinical interdepartmental review with a view to improving knowledge and patient care for the public benefit.
- Providing careers advice to the public about endocrinology, with the aim of attracting high-calibre scientists, doctors and nurses into endocrinology to improve research, education and patient care.
- Monitoring the basic science education and careers support activities of the Society at graduate level and above.

Achievements and performance

The Society's website received 162,886 (an increase of 12%) visits from 106,471 unique users (an increase of 13%). The most popular areas of the website were Meetings, Grants and Journals.

- The Society's Special Interest Groups (now being remodelled as "Endocrine Networks") have had input into meeting programmes and provided networking opportunities for members. They have continued to enhance Society activities; writing guidelines, patient information sheets and collaborating with other key stakeholders
- To date one Endocrine Network has been established - ENREB (Endocrine Network in Reproductive Endocrinology and Biology). The network has provided input to the Wellcome Trust statement supporting funding for stem cell and reproductive health research in Europe, successfully bid to host an ESE Basic Endocrinology course and provided suggestions for SfE BES 2015
- 14 nurses have gained their Certificate in Adult Endocrine Nursing.
- The Society has produced emergency clinical guidance aimed at medical staff in emergency departments on how to treat patients when they first present to A and E before an Endocrinologist is likely to become involved in patient care. These conditions are often time critical and can be fatal if the initial assessment and necessary treatment is not given as soon as possible.
- The UK Acromegaly Register and CaHASE research projects continue to gather valuable data presenting at international meetings (SfE BES 2014, ECE 2014 and ENDO 2014) and publishing in peer reviewed journals. Press releases were also sent out that were covered in specialist The Society project manages additional research projects on pituitary apoplexy, transitional care and management of patients with Grave's disease. These projects are currently in the patient recruitment phase.
- The Society has been a major contributor to the Society of Biology (SB), both financially and in terms of input from members and staff. During the period, the Society participated in all relevant task forces and has a representative member on the Animal Science Group. The Society also part funds a Society of Biology policy post, enabling liaison and collaboration with key parliamentary stakeholders.

Volunteers

The Society depends very largely for its success on the time and commitment devoted to it by a large body of volunteers – scientists, clinicians and nurses around the world. Approximately 100 members sit on committees, 110 members and non-members currently serve on journal editorial boards, and many more assist with programme development for meetings, as speakers and chairs, and with other activities. The Society is immensely grateful to all these volunteers for their tireless work.

Investment policy and performance

The investment portfolio is managed by Brewin Dolphin Limited under a discretionary investment management arrangement. There are no restrictions on the Charity's power to invest. The investment strategy is set by the trustees and takes into account income requirements, the risk profile and the investment manager's view of the market prospects.

The policy is to maximise total return through a diversified portfolio whilst providing a level of income advised by the Trustees from time to time. There is also an Ethical Policy excluding investment not to invest in companies that derive more than 10% of their turnover from the tobacco industry or anything clearly injurious to health.

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Investment policy and performance (Continued)

The investment brokers prepare portfolio valuation reports quarterly, with additional reports prepared for each Finance Committee meeting, including comparison with the appropriate benchmarks. The Finance Committee meets three times during the year and the investment manager normally attends at least one meeting.

The value of listed investments decreased to £4,650K from £5,066K during the year, largely as a result of funds withdrawn to fund the deficit budget. The portfolio experienced unrealised gains on investments held at the year-end of £33K. Total investment income for the period was £142K (2013 - £125K). Cash reserves for the Society and Bioscientifica Limited together stood at £3,421K (2013 - £1,973K) at the year-end. This includes cash held on behalf of third parties.

The investments of the Main Fund are shown in note 14 to the accounts.

Financial review

Financial overview

The net movement in funds for the year to 31 July 2014, as shown on the Statement of Financial Activities on page 14 of the accounts, shows a decrease in surplus of £1,018K compared to the previous year. Total incoming resources are £167K up on 2013. The Voluntary income relates to royalties from *Clinical Endocrinology*, which remained on a par with last year. The trading income from Bioscientifica (as shown in note 6) is up £94K on last year, as the benefits of targeting growth and diversification start to materialise. Sponsorship & Exhibitions income increased by £80K as an increased support of events was achieved. Incoming resources from charitable activities fell back marginally by £24K, largely as a result of a fall in journal publication income. Resources expended increased by £550K compared to 2013, Society events and conferences and Membership services expenditure show increases in the cost base, which then attract larger allocations of support costs. Events costs increase as a result of attending more expensive venues and adding new services, whilst the Membership services costs reflect additional costs of resourcing new activities as identified through the strategy work. Expenditure on the Designated Strategy development activities is broadly in line with last year. Grant expenditure is lower than last year, as last year included the delayed award of the final round of the Summer 2012 Early Career Grants. The resulting deficit before gains and losses on investments is £734K (2013 – £350K deficit). The total realised and unrealised gain on investments is £17K (2013 – £652K gain). Taking all of the above into account leaves a net decrease in funds of £717K (2013 – £301K increase), which is substantially lower than the budgeted deficit of £1,000K.

Of the various individual funds, the Main Fund (pages 27-29) covers the Society's major activities. The fund showed a deficit before investment income and gains / losses of £1,347K (2013 – £1,265K deficit). The gift aid from Bioscientifica of £592K (2013 - £915K) is included in the total investment income of £727K (2013 - £1,033K), representing the major source of funding of the Society's activities.

During 2012, Council earmarked £700K for the strategic activities. The fund stood at £453K at the year-end and the Trustees consider that it remains appropriate to retain this fund for the continued development of strategic activities.

Council set a substantial deficit budget for the year with the intention of reducing the surplus reserves. The Main Fund results show a deficit of £601K (2013 – surplus of £668K).

<i>Other fund results</i>	<i>Surplus/(deficit)</i>	<i>Carried forward</i>
	<i>£000</i>	<i>£000</i>
Marjorie Robinson Fund	(3)	275
Acromegaly Project Fund	3	64
CAHASE Project Fund	(2)	1
Pituitary Apoplexy Fund	(2)	8
Graves' Disease Fund	(1)	12
Transition Study Fund	(1)	2

Reserves policy

During the year, Council reviewed the basis of the reserves policy and the methodology for arriving at the figure for the required reserves. They concluded that the basis should remain the same and the revised methodology allows Council to review the extent to which they will continue to support activities in times of financial hardship.

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

The Society for Endocrinology is the main organisation representing endocrinology in the UK. It organises meetings and training courses, and provides grants, publications and other activities to advance the understanding of endocrinology for the public benefit.

To date, funding has been derived mainly from surpluses from trading company activities, including publishing and event management, and income from investments.

The reserves policy assumes that, in the event of severe financial crisis, the Society would require sufficient funds to run on a going concern basis for a two year period, during which the Society's position would be evaluated. Existing projects would be financed for up to two years at a level based on priorities agreed by Council. In the event that no viable alternatives for financing could be identified, the Society would be wound up. It has been assumed that the sale of the office premises would provide sufficient funds to cover any associated costs.

Conclusion - The Trustees consider that the required level of readily usable reserves, calculated as the value of the group net assets in the Main Fund less the values of the tangible fixed assets as shown in note 21 and the designated funds as at note 18, should be £3.44M. The figure for readily available reserves was £3.9M at 31 July 2014 (compared with a figure of £4.5M at 31 July 2013). Therefore, the free reserves exceeded the requirement at that time by £0.5M (2013 £1.48M).

Taking into account designated strategy funds, the Trustees have £950K within their control before breaching the level of the reserve requirement.

It was previously agreed that the surplus of £2.07M should be reduced by 50% by July 2014, which has been achieved by the transfer to the designated strategy funds and the continued policy of setting deficit budgets.

Bioscientifica Limited

Bioscientifica Limited's profit before gift aid and taxation of £610K (2013: £943K) for the year represents a strong performance in the light of the anticipated reduction in activity and investment in new product development. Bioscientifica's international customer profile provides some protection from regional economic issues and although the economic climate remains uncertain there are opportunities for new business growth that have been developed during the period.

Bioscientifica Limited generates funds for the Society by providing products and services to third parties in areas where the Society's staff have expertise. This also allows cost-effective sharing of overheads. Bioscientifica's main areas of activity are publishing (journals, books), event organising (conferences, workshops, investigators' meetings and training courses), association management provision (secretariat services, newsletters, public & media relations and website management). The main customer and client groups are scientific & medical societies, the pharmaceutical industry, international universities and research institutions. A summary of financial results is shown in note 3 to the accounts, and Bioscientifica will remit to the Society the sum of £592K for the financial year to 31 July 2014. Bioscientifica has a retained reserve of £50K brought forward from previous years.

The Bioscientifica Limited annual business plan forms the basis of current and future activity across the company's main divisions and identifies targets for product development and growth as well as operational and strategic risks to the company. Business strategy is predicated on growth and development within both publishing and client services, and on the consolidation of major client relationships.

Risk review

The Society's risk management statement was reviewed in full in January 2014 and will be revised by the Society's Council of Management in December 2014. The document is supported by other specific documents, including a Health and Safety Statement, fire and security regulations, financial scenario planning models and risk assessment registers for the Society and Bioscientifica.

Key current risks include:

- Reliance of GiftAid income from Bioscientifica Ltd as the Society's major source of income
- Management of major infrastructure projects
- The changing nature of the pharmaceutical industry and the need to manage the relationship between the Society and commercial sponsors carefully.

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Plans for future periods

Strategy

The Society's 2012-15 strategic plan is well under way, with a designated fund identified to pay for defined strategic projects. The strategy was approved by Council in January 2012, and provides an opportunity to refocus Society activities into clearly defined areas. The long term objective is to create an organisation that is a world leading authority on hormones. In order to achieve this clear targets and milestones have been set, with the Council reviewing progress at regular meetings.

Council have strongly endorsed this approach. The Society has been in the fortunate position to have a strong level of reserves, and the implementation of new and sustainable initiatives can be achieved whilst maintaining this solid base.

The Society's trustees and staff are acutely aware of the wide range of external variables currently deemed unstable and make use of a scenario planning tool that allows the Trustees, Finance Committee and staff to be aware of the effects of changes to external variables and of their own proposed decisions on the Society's longer-term financial health

A major review of Society meetings, events and education provision was undertaken in 2013, and this has resulted in a range of projects currently underway to deliver the Society's strategic objectives.

Future plans include focusing activity on trainees and scientists in training, developing online educational resources and rolling out a series of focused themed scientific meetings to enhance the Society's reach and profile.

Statement of Trustees' responsibilities

The Trustees (who are also Directors of the Society for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company and charity law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the Trustees are aware:

- There is no relevant information of which the society's auditor is not aware and
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

SOCIETY FOR ENDOCRINOLOGY

REPORT OF THE COUNCIL OF MANAGEMENT

Funds held as custodian trustee on behalf of others

Within Bioscientifica Limited are held funds of £2,729K belonging to clients of the company. These funds relate to contracts which involve Bioscientifica collecting and holding income on behalf of clients that is usually utilised to pay client expenditure before remitting the surplus to the client.

Auditors

A resolution proposing the re-appointment of haysmacintyre as auditors of the Society will be put to the members at the Annual General Meeting.

Registered Office: 22 Apex Court
 Woodlands
 Bradley Stoke
 Bristol
 BS32 4JT

In approving this Trustees' Report, the Trustees are also approving the Strategic Report included here in their capacity as Company Directors.

By order of the Council and signed on their behalf by

DW Ray

General Secretary

11 December 2014

SOCIETY FOR ENDOCRINOLOGY

Independent Auditor's Report to the Members and Trustees of Society for Endocrinology

We have audited the financial statements of Society for Endocrinology for the year ended 31 July 2014 which comprise the Consolidated Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Consolidated Cash Flow Statement and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinion we have formed.

Respective responsibilities of trustees and auditor

As explained more fully in the Statement of Trustees' Responsibilities set out on page 11, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the Financial Reporting Council's website at www.frc.org.uk/auditscopeukprivate.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 July 2014 and of its incoming resources and application of resources, including the group's and the parent income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Report of the Council of Management for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- the charitable company and group has not kept adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the consolidated charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Kathryn Burton (Senior Statutory Auditor)
for and on behalf of haysmacintyre
Chartered Accountants and Statutory Auditors
Date: 11 December 2014

26 Red Lion Square
London
WC1R 4AG

SOCIETY FOR ENDOCRINOLOGY

**Consolidated statement of financial activities for the year ended 31 July 2014
incorporating the income and expenditure account**

	Note	Unrestricted funds £	Restricted funds £	Endowment fund £	2014 Total £	2013 Total £
Incoming resources						
<i>Incoming resources from charitable activities</i>	4	1,991,992	27,634	-	2,019,626	2,043,441
<i>Incoming resources from generated funds</i>						
Voluntary income	5	139,944	-	-	139,944	140,420
Activities for generating funds	6	2,620,875	-	-	2,620,875	2,446,376
Investment income		135,931	-	6,059	141,990	125,289
Total incoming resources		<u>4,888,742</u>	<u>27,634</u>	<u>6,059</u>	<u>4,922,435</u>	<u>4,755,526</u>
Resources expended						
<i>Charitable activities</i>	7	2,633,163	35,409	-	2,668,572	2,451,882
<i>Cost of generating funds</i>						
Cost of generating voluntary income		3,575	-	-	3,575	5,364
Fundraising trading: cost of goods sold and other costs	8	2,810,240	-	-	2,810,240	2,470,228
Investment management costs		25,068	-	1,416	26,484	13,127
<i>Governance costs</i>	9	147,294	-	-	147,294	165,499
Total resources expended		<u>5,619,340</u>	<u>35,409</u>	<u>1,416</u>	<u>5,656,165</u>	<u>5,106,100</u>
Net (outgoing)/incoming resources before transfers						
Transfers between funds	11	(730,598)	(7,775)	4,643	(733,730)	(350,574)
		<u>1,000</u>	<u>278,597</u>	<u>(279,597)</u>	<u>-</u>	<u>-</u>
Net (outgoing)/incoming resources before other recognised gains						
Realised gains/ (losses) for the year		(729,598)	270,822	(274,954)	(733,730)	(350,574)
		<u>(16,098)</u>	<u>-</u>	<u>-</u>	<u>(16,098)</u>	<u>289,661</u>
(Deficit)/surplus for the year						
Unrealised gains/(losses) on investment assets		(745,696)	270,822	(274,954)	(749,828)	(60,913)
		<u>35,439</u>	<u>-</u>	<u>(2,791)</u>	<u>32,648</u>	<u>361,976</u>
Net movement in funds		<u>(710,257)</u>	<u>270,822</u>	<u>(277,745)</u>	<u>(717,180)</u>	<u>301,063</u>
Total funds at 1 August 2013						
		<u>6,170,911</u>	<u>91,510</u>	<u>277,745</u>	<u>6,540,166</u>	<u>6,239,103</u>
Total funds at 31 July 2014						
		<u>5,460,654</u>	<u>362,332</u>	<u>-</u>	<u>5,822,986</u>	<u>6,540,166</u>

All of the above amounts relate to continuing activities.

The notes on pages 17 to 26 form part of these financial statements

SOCIETY FOR ENDOCRINOLOGY

Consolidated and Charity balance sheets at 31 July 2014

	Note	Group 2014 £	Charity 2014 £	Group 2013 £	Charity 2013 £
Fixed assets					
Tangible assets	13	1,068,715	1,040,720	1,138,516	1,106,254
Listed investments	14	4,650,065	4,650,065	5,065,777	5,065,777
Investment in Bioscientifica Limited		-	1,000	-	1,000
		<u>5,718,780</u>	<u>5,691,785</u>	<u>6,204,293</u>	<u>6,173,031</u>
Current assets					
Debtors	15	961,013	251,244	975,563	288,009
Cash at bank and in hand	16	3,421,447	320,813	1,973,150	384,857
		4,382,460	572,057	2,948,713	672,866
Creditors					
Amounts falling due within one year	17	4,278,254	489,865	2,612,840	354,740
Net current assets		<u>104,206</u>	<u>82,192</u>	<u>335,873</u>	<u>318,126</u>
Total assets less current liabilities		<u>5,822,986</u>	<u>5,773,977</u>	<u>6,540,166</u>	<u>6,491,157</u>
Funds					
Unrestricted:					
Main Fund	18	4,958,241	4,958,241	5,559,490	5,559,490
Designated Strategy Fund		453,404	453,404	562,412	562,412
Bioscientifica Limited		49,009	-	49,009	-
		<u>5,460,654</u>	<u>5,411,645</u>	<u>6,170,911</u>	<u>6,121,902</u>
Restricted:					
Acromegaly Fund	19	64,208	64,208	61,307	61,307
CaHASE Fund		1,284	1,284	3,483	3,483
Pituitary Apoplexy		8,065	8,065	10,152	10,152
Graves' Disease		12,261	12,261	13,643	13,643
Transition Study		1,917	1,917	2,925	2,925
The Marjorie Robinson fund		274,597	274,597	-	-
		<u>362,332</u>	<u>362,332</u>	<u>91,510</u>	<u>91,510</u>
Endowment:					
The Marjorie Robinson fund	20	-	-	277,745	277,745
		<u>5,822,986</u>	<u>5,773,977</u>	<u>6,540,166</u>	<u>6,491,157</u>

These financial statements were approved by the directors and authorised for issue on 11 December 2014, and are signed on their behalf by:

D W RAY

GENERAL SECRETARY

G R WILLIAMS

TREASURER

Company registration number: 349408.

The notes on pages 17 to 26 form part of these financial statements

SOCIETY FOR ENDOCRINOLOGY

Consolidated cashflow statement for the year ended 31 July 2014

	Note	2014	2013
		£	£
Net cash inflow/(outflow) from operating activities	a	948,019	(702,966)
Returns on investments and servicing of finance			
Dividends received		140,590	119,563
Interest received		<u>1,400</u>	<u>5,726</u>
Cash inflow from returns on investment and servicing of finance		<u>141,990</u>	<u>125,289</u>
Capital expenditure			
Payments to acquire fixed assets		(74,294)	(439,108)
Purchase of investments		(472,232)	(3,522,396)
Movement in cash awaiting investment		58,669	15,247
Proceeds from sale of investment property		-	-
Proceeds from sale of fixed assets		320	2,565
Proceeds from sale of investments		<u>845,795</u>	<u>3,510,802</u>
Cash inflow/(outflow) from capital expenditure		<u>358,288</u>	<u>(432,890)</u>
Increase /(Decrease) in cash during year	c	<u>1,448,297</u>	<u>(1,010,567)</u>

Notes to Cashflow Statement

a: Reconciliation of net incoming resources to net cash outflow from operating activities

Net incoming/(outgoing) resources	(717,180)	301,063
Dividends received	(140,590)	(119,563)
Interest received	(1,400)	(5,726)
Decrease/(increase) in debtors	14,550	(532,063)
Increase/(decrease) in creditors	1,665,414	(553,648)
Depreciation	144,095	102,712
Loss on disposal of investment property	-	-
Loss on disposal of tangible assets	320	44,327
Unrealised gains on investment	(32,648)	(361,976)
Realised losses/(gains) on investment	<u>16,098</u>	<u>(289,661)</u>
Net cash inflow/(outflow) from operating activities	<u>948,019</u>	<u>(702,966)</u>

b: Reconciliation of net cash outflow to movement in net funds

Increase /(Decrease) in cash in the year	473,135	(525,453)
Movement in short term deposits in the year	975,162	(485,114)
Opening net funds	<u>1,973,150</u>	<u>2,983,717</u>
Closing net funds	<u>3,421,447</u>	<u>1,973,150</u>

c: Analysis of changes in net debt

	1 August 2013	Cash Flows	31 July 2014
Cash at bank and in hand	367,455	473,135	840,590
Short term deposits	<u>1,605,695</u>	<u>975,162</u>	<u>2,580,857</u>
Net cash outflow from operating activities	<u>1,973,150</u>	<u>1,448,297</u>	<u>3,421,447</u>

SOCIETY FOR ENDOCRINOLOGY

Notes to the accounts for the year ended 31 July 2014

1. Accounting policies

The financial statements have been prepared under the historical cost convention, as modified by the revaluation of certain fixed assets, and in accordance with the Statement of Recommended Practice, Accounting and Reporting by Charities (SORP 2005) issued in March 2005, with applicable accounting standards and the Companies Act 2006.

The statement of financial activities (SOFA) and balance sheet consolidate the financial statements of the charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line-by-line basis.

The charity has taken exemption from presenting a separate statement of financial activities under section 408 of the Companies Act 2006. The parent undertakings' total deficit for the year was £717,180 (2013: surplus of £301,063).

a) Listed investments and investment property

Listed investments are stated at market value at the year-end.

Gains and losses on disposal and revaluation of investments are charged or credited to the SOFA.

b) Depreciation

Fixed assets are capitalised where the total cost exceeds £200.

Depreciation is provided on all tangible assets other than freehold land to write off the cost, less estimated residual value of each asset over its expected useful life.

The estimated useful lives are as follows:

Buildings	: 50 years
Freehold Improvements, Fixtures and Fittings	: 5 to 10 years
Office Equipment	: 3 to 5 years

c) Pensions

The Society contributes to the personal pension arrangements of certain staff. The assets are held separately from those of the Society in independently administered funds. The contributions are charged to the statement of financial activities on a payments basis. The contributions paid are shown in note 12.

d) Incoming resources

Income includes:-

- i. Donations received during the year
- ii. Grants and royalties which are accounted for on a receivable basis
- iii. Investment income received during the period includes dividends and bank interest, on an accruals basis
- iv. Subscriptions which are accounted for on the accruals basis and deferred if paid in advance
- v. Sponsorship, event income and book other publication income are recognised when delivered

e) Resources expended and basis of allocation of costs

Expenditure is included when incurred and is matched with the relevant income stream.

Governance costs include items such as Council and committee expenses, costs of meeting constitutional and statutory requirements, financial reporting costs and an apportionment of support costs.

Grants payable are recognised when the amount of the award is fixed, approved and verified.

All other costs are attributed as set out in notes 1g) to 1n) below.

f) Costs of generating funds

These include all costs of the activities of the trading subsidiary (excluding the Society-owned publications), investment managers' fees and any costs associated with generating voluntary income.

g) Costs of Charitable activities

This represents the costs that relate to the generation of income to further the charity's objects.

h) Support costs

Support costs shown in note 10 represent the indirect costs incurred in providing support for all activities of the charity. These have been allocated on the basis of the direct costs of the relevant activity.

SOCIETY FOR ENDOCRINOLOGY

Notes to the accounts for the year ended 31 July 2014 (continued)

i) Foreign currencies

Transactions in foreign currencies are translated at rates prevailing at the date of the transaction. Bank balances denominated in foreign currencies are translated at the rate of exchange prevailing at the year-end.

j) Fund accounting

The nature and purpose of each fund are explained in notes 18, 19 and 20.

k) Client accounts

The accounts held separately within debtors and creditors represent separate funds in respect of clients for whom the Society's subsidiary acts as an agent.

l) Operating lease agreements

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged against profits on a straight-line basis over the period of the lease

m) Taxation

The charitable company is exempt from corporation tax under S505 of the Income and Corporation Taxes Act 1988.

2. Incoming resources

An analysis of incoming resources by geographical location is given below:

	2014	2013
	Group	Group
	%	%
United Kingdom	39	39
Europe	39	36
North America	13	16
Rest of the World	9	9
	<u>100</u>	<u>100</u>

3. Net income from trading activities of subsidiary

The Society owns 1000 ordinary shares of £1 each at a total value of £1,000, representing the whole of the issued share capital of Bioscientifica Limited, a company incorporated in the United Kingdom. Bioscientifica Limited carries out journal and book publishing projects as well as providing conference and other services to the scientific community. A summary of the trading results is set out below.

Summary profit and loss account

	2014	2013
	£	£
Turnover	3,975,683	3,869,256
Cost of sales	<u>1,834,269</u>	<u>1,625,927</u>
Gross profit	2,141,414	2,243,329
Administration	<u>1,560,583</u>	<u>1,332,102</u>
Operating profit	580,831	911,227
Interest receivable and similar income	<u>29,382</u>	<u>31,975</u>
Profit on ordinary activities	610,213	943,202
Gift Aid	<u>(610,213)</u>	<u>(943,202)</u>
Profit before taxation	-	-
Taxation	<u>-</u>	<u>-</u>
Retained in subsidiary	<u>-</u>	<u>-</u>

SOCIETY FOR ENDOCRINOLOGY

Notes to the accounts for the year ended 31 July 2014 (continued)

3. Net income from trading activities of subsidiary (Continued)

	2014 £	2013 £
Total assets and liabilities of the subsidiary were:		
Fixed assets	27,995	32,262
Current assets	3,917,274	2,323,361
Creditors: amounts falling due within one year	<u>(3,895,260)</u>	<u>(2,305,614)</u>
 Total net assets	 <u>50,009</u>	 <u>50,009</u>
 Aggregate share capital and reserves	 <u>50,009</u>	 <u>50,009</u>

The gift aid for the year of £610,213 was distributed as follows, £591,906 to the Society for Endocrinology and £18,307 to the Bioscientifica trust.

4. Incoming resources from charitable activities

	Unrestricted funds £	Restricted funds £	Endowment fund £	2014 Total £	2013 Total £
Publications	1,380,268	-	-	1,380,268	1,400,847
Society events and conferences (see below)	432,753	-	-	432,753	455,397
Other membership services (including subscriptions)	150,486	-	-	150,486	130,306
Grants received	<u>28,485</u>	<u>27,634</u>	-	<u>56,119</u>	<u>56,891</u>
	<u>1,991,992</u>	<u>27,634</u>	-	<u>2,019,626</u>	<u>2,043,441</u>

Income from Society events and conferences includes:

	£	£
The Society annual meeting	295,705	309,879
Training and other registration fees	<u>137,048</u>	<u>145,518</u>
	<u>432,753</u>	<u>455,397</u>

5. Voluntary income

	Unrestricted funds £	Restricted funds £	Endowment fund £	2014 Total £	2013 Total £
Royalties received	<u>139,944</u>	-	-	<u>139,944</u>	<u>140,420</u>

6. Activities for generating funds

	Unrestricted funds £	Restricted funds £	Endowment fund £	2014 Total £	2013 Total £
Trading income from subsidiary company	2,449,950	-	-	2,449,950	2,355,642
Sponsorship and exhibitions	<u>170,925</u>	-	-	<u>170,925</u>	<u>90,734</u>
	<u>2,620,875</u>	<u>-</u>	<u>-</u>	<u>2,620,875</u>	<u>2,446,376</u>

SOCIETY FOR ENDOCRINOLOGY

Notes to the accounts for the year ended 31 July 2014 (continued)

7. Charitable activities

	Direct costs £	Grants paid £	Support costs (note 10) £	2014 Total £	2013 Total £
Publications	602,919	-	-	602,919	536,444
Society events and conferences	596,376	-	214,716	811,092	683,203
Other membership services (including subscriptions paid)	385,183	591,282	138,679	1,115,144	1,053,940
Designated Strategy Fund	109,008	-	-	109,008	118,102
Society research projects	31,409	-	-	31,409	60,193
	<u>1,747,116</u>	<u>591,282</u>	<u>353,395</u>	<u>2,668,572</u>	<u>2,451,882</u>

Subscriptions paid by the group include the following:

	2014 £	2013 £
Society of Biology	30,000	30,000
International Society of Endocrinology	4,191	4,271
Sense about Science	3,000	-
Alpha Galileo	1,772	-
Foundation for Science and Technology	203	160
Understanding Animal Research	547	521
Association of Medical Research Charities	1,772	1,231
Parliamentary and Scientific Committee	325	325
	<u>325</u>	<u>325</u>

Grants paid are made up as follows:

	No.	Grants paid £	Staff and other costs £	2014 £	2013 £
<i>Grants payable to individuals:</i>					
Individual grants for attendance at meetings and conferences	270	170,795	2,639	173,434	185,830
Summer Studentships	23	64,229	3,378	67,607	68,487
Early Career Grants	26	249,377	13,495	262,872	361,126
Practical Skills Grants	6	8,700	820	9,520	15,707
<i>Total grants payable to individuals</i>		<u>493,101</u>	<u>20,332</u>	<u>513,433</u>	<u>631,150</u>
<i>Grants payable to institutions:</i>					
Patient support grants	20	29,778	4,270	34,048	-
Public engagement grants	3	2,493	-	2,493	1,101
Undergraduate Achievement Award	6	5,400	-	5,400	9,900
Other grants	13	35,155	753	35,908	32,854
<i>Total grants payable to institutions</i>		<u>72,826</u>	<u>5,023</u>	<u>77,849</u>	<u>43,855</u>
Total grants paid		<u>565,927</u>	<u>25,355</u>	<u>591,282</u>	<u>675,005</u>

Grants payable to individuals may be made payable to the workplace for the benefit of the individual.

SOCIETY FOR ENDOCRINOLOGY

Notes to the accounts for the year ended 31 July 2014 (continued)

8. Fundraising trading

	2014 £	2013 £
Trading costs of subsidiary company	2,810,240	2,440,881
Sponsorship and exhibitions	<u>-</u>	<u>29,347</u>
	<u>2,810,240</u>	<u>2,470,228</u>

9. Governance costs

Governance costs are made up as follows:

	2014 £	2013 £
Council and committee expenses	96,477	109,442
Statutory and constitutional costs	11,825	15,255
Support costs (note 10)	<u>38,992</u>	<u>40,802</u>
	<u>147,294</u>	<u>165,499</u>

10. Support costs

Support costs are included under:

	2014 £	2013 £
Charitable activities (note 7)	353,395	261,858
Governance costs (note 9)	<u>38,992</u>	<u>40,802</u>
	<u>392,387</u>	<u>302,660</u>

These costs are made up as follows:

	2014 £	2013 £
Finance and administration	325,715	387,432
Sales, marketing and communications	162,122	121,033
Insurance	27,011	27,254
Establishment	84,673	145,825
IT and communications	111,638	121,618
Depreciation	136,475	145,341
Less overheads recharged	<u>(455,247)</u>	<u>(645,843)</u>
	<u>392,387</u>	<u>302,660</u>

11. Net (expenditure)/income for the year

	2014 £	2013 £
This is stated after charging:		
Depreciation	144,095	102,712
(Profit)/Loss on disposal of fixed assets	(320)	44,327
Auditors' remuneration:		
Audit services	13,325	13,325
Accountancy and other services	<u>-</u>	<u>425</u>

SOCIETY FOR ENDOCRINOLOGY

Notes to the accounts for the year ended 31 July 2014 (continued)

12. Staff costs

Staff costs during the year amounted to:

	2014 £	2013 £
Salaries	1,931,844	1,769,787
Social security costs	183,334	172,165
Other pension costs	<u>102,940</u>	<u>96,520</u>
	<u>2,218,118</u>	<u>2,038,472</u>

The number of employees whose remuneration was within the bands stated was as follows:

	Number	Number
£60,001 - £70,000	3	3
£100,001 - £110,000	-	1
£110,001 - £120,000	<u>1</u>	<u>-</u>

The average number of employees (full-time equivalent) analysed by function was:

	Number	Number
Charitable activities	45	41
Administration	<u>15</u>	<u>14</u>
	<u>60</u>	<u>55</u>

The members of the Council of Management received no remuneration for their services (2013: £Nil).

Travel and subsistence expenses were reimbursed to 12 current and past members of the Council of Management totalling £10,057 (2013: 10 members, £9,294)

The Society holds indemnity insurance to indemnify the Society, its employees and agents in respect of neglect and default on their part. The cost of insurance was £16,867 (2013: £15,688).

13. Tangible assets

	Freehold land and buildings	Leasehold premises	Freehold improvements, fixtures & fittings	Office Equipment	Charity Total	Development Costs	Group Total
Cost:	£	£	£	£	£	£	£
1 August 2013	848,017	-	330,006	326,211	1,504,234	33,960	1,538,194
Additions	-	-	9,011	62,253	71,264	3,030	74,294
31 July 2014	<u>848,017</u>	<u>-</u>	<u>339,017</u>	<u>388,464</u>	<u>1,575,498</u>	<u>36,990</u>	<u>1,612,488</u>
Depreciation:							
1 August 2013	173,841	-	47,878	176,261	397,980	1,698	399,678
Provided this year	17,024	-	62,860	56,914	136,798	7,297	144,095
31 July 2014	<u>190,865</u>	<u>-</u>	<u>110,738</u>	<u>233,175</u>	<u>534,778</u>	<u>8,995</u>	<u>543,773</u>
Net book value:							
31 July 2014	<u>657,152</u>	<u>-</u>	<u>228,279</u>	<u>155,289</u>	<u>1,040,720</u>	<u>27,995</u>	<u>1,068,715</u>
31 July 2013	<u>674,176</u>	<u>-</u>	<u>282,128</u>	<u>149,950</u>	<u>1,106,254</u>	<u>32,262</u>	<u>1,138,516</u>

SOCIETY FOR ENDOCRINOLOGY

Notes to the accounts for the year ended 31 July 2014 (continued)

14. Listed investments

	Group and Charity 2014 £	Group and Charity 2013 £
Market value on 1 August 2013	5,065,777	4,417,793
Additions	472,232	3,522,396
Disposals	(861,893)	(3,221,141)
Movement in cash awaiting investment	(58,699)	(15,247)
Net unrealised investment gains/(losses)	<u>32,648</u>	<u>361,976</u>
Market value on 31 July 2014	<u>4,650,065</u>	<u>5,065,777</u>
	£	£
The market value at 31 July 2014 comprises:		
Listed investments	4,615,680	4,964,744
Cash awaiting investment	<u>34,385</u>	<u>101,033</u>
	<u>4,650,065</u>	<u>5,065,777</u>

The historical cost of investments was £3,983,542 (2013: £4,347,669). At 31 July 2014, there were no individual holdings which represented at least 5% of the total value of listed investments.

15. Debtors

	Group 2014 £	Charity 2014 £	Group 2013 £	Charity 2013 £
Clients' accounts	328,960	-	490,054	-
Trade and other debtors	440,235	66,473	319,257	65,347
Amounts due from subsidiary	-	106,870	-	142,869
Prepayments and accrued income	<u>191,818</u>	<u>77,901</u>	<u>166,252</u>	<u>79,793</u>
	<u>961,013</u>	<u>251,244</u>	<u>975,563</u>	<u>288,009</u>

16. Cash at bank and in hand

	Group 2014 £	Charity 2014 £	Group 2013 £	Charity 2013 £
Bank current accounts	829,469	(21,420)	353,717	(264,441)
Monies held on deposit	2,580,857	340,329	1,605,695	647,499
Petty cash	<u>11,121</u>	<u>1,904</u>	<u>13,738</u>	<u>1,799</u>
	<u>3,421,447</u>	<u>320,813</u>	<u>1,973,150</u>	<u>384,857</u>

A significant proportion of income is received by way of annual subscriptions paid in advance; balances at the bank include funds to cover expenditure incurred during the remaining five months of the calendar year. The Group balances include funds held in respect of the activities of clients of the trading subsidiary.

SOCIETY FOR ENDOCRINOLOGY

Notes to the accounts for the year ended 31 July 2014 (continued)

17. Creditors: Amounts falling due within one year	Group 2014 £	Charity 2014 £	Group 2013 £	Charity 2013 £
Trade creditors	165,411	120,552	157,934	77,186
Clients' accounts	3,058,077	-	1,659,957	-
Deferred income	525,843	84,190	624,560	158,650
Other taxes and social security	113,826	113,826	60,778	61,906
Other creditors and accruals	415,097	171,297	109,611	56,998
	<u>4,278,254</u>	<u>489,865</u>	<u>2,612,840</u>	<u>354,740</u>

Deferred income

Deferred income at 1 August 2013	624,560	158,650
Resources deferred in year	525,843	84,190
Amounts taken to income in the year	<u>(624,560)</u>	<u>(158,650)</u>

Deferred income at 31 July 2014	<u>525,843</u>	<u>84,190</u>
---------------------------------	----------------	---------------

18. Unrestricted funds

	Balance 1 August 2013 £	Movement in resources		Transfer between funds £	Investment Gains / (Losses) £	Balance 31 July 2014 £
		Incoming £	Outgoing £			
Main Fund	5,559,490	1,640,229	(2,261,819)	1,000	19,341	4,958,241
Designated Strategy Fund	562,412	-	(109,088)	-	-	453,404
Bioscientifica Limited	49,009	3,248,513	(3,248,513)	-	-	49,009
	<u>6,170,911</u>	<u>4,888,742</u>	<u>(5,619,340)</u>	<u>1,000</u>	<u>19,341</u>	<u>5,460,654</u>

Bioscientifica Limited profits of £591,906K were transferred to the Main Fund as gift aid.

In 2012, the trustees allocated £700,000 to the designated strategy fund to meet the costs of the new strategic initiatives. These projects have continued to be developed during the year. The remaining funds are expected to be utilised over the next two years.

19. Restricted funds

	Balance 1 August 2013 £	Movement in resources		Transfer between funds £	Investment Gains / (Losses) £	Balance 31 July 2014 £
		Incoming £	Outgoing £			
Acromegaly Fund	61,307	22,500	(23,599)	4,000	-	64,208
CaHASE Fund	3,483	-	(2,199)	-	-	1,284
Pituitary Apoplexy	10,152	-	(2,087)	-	-	8,065
Graves' Disease	13,643	-	(1,382)	-	-	12,261
Transition Study	2,925	5,134	(6,142)	-	-	1,917
Marjorie Robinson Fund	-	-	-	274,597	-	274,597
	<u>91,510</u>	<u>27,634</u>	<u>(35,409)</u>	<u>278,597</u>	<u>-</u>	<u>362,332</u>

SOCIETY FOR ENDOCRINOLOGY

Notes to the accounts for the year ended 31 July 2014 (continued)

19 Restricted funds (continued)

The Acromegaly fund is used to finance the administration of a national research register on a rare disease called acromegaly.

The CaHASE fund is used to run a project which aims to provide further understanding of the rare disease called congenital adrenal hyperplasia.

The Pituitary Apoplexy fund is used to finance the audit of the Society's guidance on the rare emergency condition of apoplexy.

The Graves' Disease fund is used to finance the audit of patient outcomes after radioiodine treatment.

The Transition Study is used to finance the evaluation of transitional care in endocrinology.

20. Endowment fund

	Balance 1 August 2013 £	Movement in resources		Transfer between funds £	Investment Gains / (Losses) £	Balance 31 July 2014 £
		Incoming £	Outgoing £			
The Marjorie Robinson Fund	<u>277,745</u>	<u>6,059</u>	<u>(1,416)</u>	<u>(279,597)</u>	<u>(2,791)</u>	<u>-</u>

Miss Robinson left a legacy to the Charity to provide for research into pituitary and/or adrenal disease. During the year the Council of Management reviewed terms of the original legacy and, having taken advice from the auditors and Charity Commission, concluded that this fund should be reclassified as a restricted fund. Consequently the funds were transferred to restricted funds as at the end of the year.

21. Analysis of group net assets between funds

	Unrestricted funds £	Restricted funds £	Endowment fund £	Transfer between funds £	2014 Total £	2013 Total £
Tangible fixed assets	1,068,715	-	-	-	1,068,715	1,138,516
Listed investments	4,390,647	259,418	-	-	4,650,065	5,065,777
Debtors	961,508	102,914	-	(103,409)	961,013	975,563
Cash at bank and in hand	3,421,447	-	-	-	3,421,447	1,973,150
Creditors	<u>(4,381,663)</u>	<u>-</u>	<u>-</u>	<u>103,409</u>	<u>(4,278,254)</u>	<u>(2,612,840)</u>
	<u>5,460,654</u>	<u>362,332</u>	<u>-</u>	<u>-</u>	<u>5,822,986</u>	<u>6,540,166</u>

22. Transfers between funds

During the year the following transfers were made between funds:

	2014 £	2013 £
<i>From the Main Fund to:</i>		
Acromegaly Fund to contribute to the support costs of the fund	4,000	4,000
CaHase Fund to contribute to the support costs of the fund	<u>-</u>	<u>1,200</u>
<i>From the Marjorie Robinson Endowment Fund to:</i>		
Marjorie Robinson Restricted Fund	274,597	
Main Fund to support grants for research into pituitary and/or adrenal disease	<u>5,000</u>	<u>4,000</u>

SOCIETY FOR ENDOCRINOLOGY

Notes to the accounts for the year ended 31 July 2014 (continued)

23. Commitments under operating leases

At 31 July 2014 the Society had aggregate annual commitments under non-cancellable operating leases as set out below:

	2014 £	2013 £
Operating leases which expire:		
Within 1 year	-	5140
	<hr/>	<hr/>

24. Capital commitments

Capital commitments contracted and authorised at the year end were £Nil (2013: £Nil).

Capital commitments authorised but not contracted at the year end were £267,000 (2013: £Nil)

25. Related party transactions

The charity has taken advantage of the exemption available under FRS8 not to disclose transactions with the subsidiary company.

Where members of the Council of Management are in a position to exercise significant influence they declare their interest and exclude themselves from any relevant discussions. In extreme cases, where this approach is not sufficient, discussions are held with the individual regarding standing down from one of the organisations.

No other related party transactions have occurred in the year

26. Contingent liabilities

There were no contingent liabilities at the year-end.

